EMA panel issues negative opinion on Omeros narsoplimab application
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
June 26, 2026 8:30 AM EDTSEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the companys marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
Following an oral explanation meeting with the CHMP held this week, at which Omeros presented its position together with four international experts in hematopoietic cell transplantation, Omeros was informed that the CHMP has adopted a negative opinion on the MAA... More
